MGMT and glioma: In glioma, it is well known that O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status is both prognostic and predictive of treatment outcome with temozolomide, so treatment decisions in clinical routine for glioblastoma are mainly based on it.